GlaxoSmithKline, Medicinal Science & Technology, Collegeville, Pennsylvania PA. University of the Sciences, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA.
J Pharm Pharm Sci. 2019;22(1):221-246. doi: 10.18433/jpps30347.
This study investigates the influence of surfactant sodium lauryl sulfate (SLS) on the solubility of poorly-water soluble drug substances, model Compound X and Compound Y, used in a fixed dose combination oral solid dosage form. To determine the impact of SLS concentration on the solubility of compounds X and Y, we experimentally determined the critical micelle concentration (CMC) of SLS in water, simulated gastric fluid (SGF), and fed state simulated intestinal fluid (FeSSIF) in the presence of Compound X and Compound Y using UV/Visible spectrophotometry at 25°C. The aggregation of SLS was characterized by calculating the standard Gibbs free energy of micellization in all the media investigated. To enhance the understanding of SLS aggregation, high throughput experiments and in-vivo mechanistic modelling were used to determine the effect of increasing levels of SLS on the solubility of compounds X and Y as both single agent and combination products to be formulated into a suitable oral solid dosage form. Micellar formation of SLS is a spontaneous process as shown by the negative values of the standard free energy of micellization. The CMC of SLS in the various media investigated in the presence of compounds X and Y decreases in the following order: water> FeSSIF> SGF. However, the aggregation of SLS in the various media is overall more spontaneous in the following order: SGF>FeSSIF>water. Using high throughput experimentation and in-vivo mechanistic modelling, it was determined that a combination oral solid product of compounds X and Y will have optimum solubility and in-vivo absorption if 2 mg of SLS was used in the oral solid dosage form. The results obtained from this study will help broaden the understanding of the micellization process involving SLS and poorly-water soluble drugs used in combination oral solid dosage forms.
本研究考察了表面活性剂十二烷基硫酸钠(SLS)对难溶性药物物质模型化合物 X 和化合物 Y 的溶解度的影响,这些药物物质用于固定剂量组合口服固体制剂。为了确定 SLS 浓度对化合物 X 和 Y 溶解度的影响,我们使用紫外/可见分光光度法在 25°C 下,在存在化合物 X 和化合物 Y 的情况下,实验确定了 SLS 在水中、模拟胃液(SGF)和 fed 状态模拟肠液(FeSSIF)中的临界胶束浓度(CMC)。通过计算所有研究介质中胶束化的标准吉布斯自由能,表征了 SLS 的聚集。为了增强对 SLS 聚集的理解,使用高通量实验和体内机制建模来确定随着 SLS 水平的增加对化合物 X 和 Y 的溶解度的影响,这些化合物 X 和 Y 作为单一药物和组合产品被配制为合适的口服固体制剂。如胶束化的标准自由能的负值所示,SLS 的胶束形成是一个自发过程。在存在化合物 X 和 Y 的情况下,在各种研究介质中的 SLS 的 CMC 按以下顺序降低:水>FeSSIF>SGF。然而,在各种介质中,SLS 的聚集总体上按以下顺序更为自发:SGF>FeSSIF>水。通过高通量实验和体内机制建模,确定如果在口服固体制剂中使用 2mg 的 SLS,则化合物 X 和 Y 的组合口服固体制剂将具有最佳的溶解度和体内吸收。本研究的结果将有助于拓宽对涉及 SLS 和组合口服固体制剂中使用的难溶性药物的胶束化过程的理解。